PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.47%
R&D growth less than half of AGEN's 1479.65%. David Dodd would verify if efficiency advantage is sustainable.
-1.59%
G&A reduction while AGEN shows 39.29% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.64%
Operating expenses growth less than half of AGEN's 39.29%. David Dodd would verify sustainability.
14.64%
Similar total costs growth to AGEN's 18.93%. Walter Schloss would investigate norms.
No Data
No Data available this quarter, please select a different quarter.
8.11%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
-14.78%
EBITDA decline while AGEN shows 40.54% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Operating income decline while AGEN shows 37.60% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Other expenses reduction while AGEN shows 4.95% growth. Joel Greenblatt would examine advantage.
-15.16%
Pre-tax income decline while AGEN shows 26.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
14.88%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
-15.16%
Net income decline while AGEN shows 26.48% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
2.78%
EPS growth below 50% of AGEN's 28.75%. Michael Burry would check for structural issues.
2.78%
Diluted EPS growth below 50% of AGEN's 28.75%. Michael Burry would check for structural issues.
19.07%
Share count reduction below 50% of AGEN's 3.28%. Michael Burry would check for concerns.
19.07%
Diluted share reduction below 50% of AGEN's 3.28%. Michael Burry would check for concerns.